Risk Factors Update Summary
- Failure to obtain or maintain regulatory approvals, particularly for brensocatib in the US, may materially adversely affect the company.
- The company experienced a one-time, prospective price decrease for ARIKAYCE in Japan of 9.4%.
- The company's accumulated deficit increased from $2.3 billion to $3.7 billion in 2023.
- The consolidated net loss increased from $481.5 million in 2022 to $749.6 million in 2023.
- The company's long-term investments were significantly higher in 2023 compared to 2022.
- The company had 124 employees located in Europe and 85 employees located in Japan as of December 31, 2023, compared to 85 and 72 employees, respectively, in 2022.
- The company's ability to generate revenue and achieve profitability may be adversely affected by increased fixed payment obligations due to potential future indebtedness.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1104506&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.